View in EDS

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Saved in:
Bibliographic Details
Title: Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Authors: Goldberg, Sarah B1 sarah.goldberg@yale.edu, Gettinger, Scott N1, Mahajan, Amit1, Chiang, Anne C1, Herbst, Roy S1, Sznol, Mario1, Tsiouris, Apostolos John2, Cohen, Justine1, Vortmeyer, Alexander1, Jilaveanu, Lucia1, Yu, James1, Hegde, Upendra3, Speaker, Stephanie1, Madura, Matthew1, Ralabate, Amanda1, Rivera, Angel1, Rowen, Elin1, Gerrish, Heather1, Yao, Xiaopan1, Chiang, Veronica1
Source: Lancet Oncology. Jul2016, Vol. 17 Issue 7, p976-983. 8p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(16)30053-5